Showing results (441-450 of 794) with videos related to
Sort By:
Pageof 80
Advances in Therapy|March 5, 2022
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisThierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.Molecular Cell|March 17, 2018
The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma CellsRuiting Lin, Siyuan Xia, Changliang Shan, et al.Life Science Alliance|December 25, 2021
Generation of human long-lived plasma cells by developmentally regulated epigenetic imprintingChester J Joyner, Ariel M Ley, Doan C Nguyen, et al.Blood|March 2, 2021
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expressionVikas A Gupta, Benjamin G Barwick, Shannon M Matulis, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2024
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic MalignanciesPinkal Desai, Sagar Lonial, Amanda Cashen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2020
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed PhenotypeTaofeek K Owonikoko, Bhakti Dwivedi, Zhengjia Chen, et al.Science Advances|September 28, 2022
Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myelomaAditi Sharma, Remya Nair, Abhinav Achreja, et al.Blood|May 25, 2016
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myelomaSaad Z Usmani, Brendan M Weiss, Torben Plesner, et al.The Lancet. Haematology|May 30, 2020
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trialsSaad Z Usmani, Hareth Nahi, Torben Plesner, et al.Transplantation and Cellular Therapy|June 21, 2021
The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic ExperienceIuliana Vaxman, Eli Muchtar, Eapen Jacob, et al.Pageof 80